New injection shows promise for tough lymphoma in early trial
NCT ID NCT07456371
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing a new biologic drug called PIC1 injection in 18 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It is too soon to know if this will become a standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PIC1 injection (a biologic therapy)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat B-cell lymphoma.
- What could go wrong
- This is a very early, small phase 1 trial with only 18 participants, so results may not apply widely. The main goal is safety, not proof of effectiveness, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- A simple blood test may reveal hidden infertility risk in young cancer survivors